KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Change in Cash (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Change in Cash for 13 consecutive years, with $94.6 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 71.8% to $94.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.5 million through Dec 2025, up 1051.8% year-over-year, with the annual reading at $56.5 million for FY2025, 1051.8% up from the prior year.
  • Change in Cash for Q4 2025 was $94.6 million at Xenon Pharmaceuticals, up from -$30.9 million in the prior quarter.
  • The five-year high for Change in Cash was $253.4 million in Q2 2022, with the low at -$266.5 million in Q3 2022.
  • Average Change in Cash over 5 years is $7.7 million, with a median of $8.6 million recorded in 2021.
  • Peak annual rise in Change in Cash hit 5113.77% in 2022, while the deepest fall reached 5562.14% in 2022.
  • Over 5 years, Change in Cash stood at $87.9 million in 2021, then plummeted by 152.63% to -$46.2 million in 2022, then surged by 206.1% to $49.1 million in 2023, then grew by 12.27% to $55.1 million in 2024, then soared by 71.8% to $94.6 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at $94.6 million, -$30.9 million, and $18.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.